Actively Recruiting
Music as an Adjunct to Ketamine Therapy for Chronic Pain
Led by McGill University · Updated on 2025-06-10
25
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
Sponsors
M
McGill University
Lead Sponsor
M
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborating Sponsor
AI-Summary
What this Trial Is About
Intravenous (IV) ketamine is a treatment option for patients with chronic pain that does not respond to standard therapies, primarily working by blocking NMDA receptors in the brain. Beyond pain relief, ketamine can produce dissociative sensations, classifying it as an atypical psychedelic or mind-altering drug, and may enable patients to reprocess their pain similarly to experiences with traditional psychedelics. At the Montreal General Hospital's pain clinic, the investigators have observed patients frequently listening to music during ketamine infusions, and recent research indicates that music-especially when self-selected by patients-might provide additional pain-relieving benefits by influencing central mechanisms related to pain perception and interpretation. This intersection of music and pain relief is garnering substantial scientific interest as recent advances provide more insight into the neuroscience of music and its effects on brain regions involved in emotion, sensation, memory, and pain. This study aims to investigate the effects of music on chronic pain patients undergoing IV ketamine infusions at the Alan Edwards Pain Management Unit (AEPMU), specifically to determine whether the choice of music affects the intensity and duration of ketamine-induced pain relief. During the infusion (lasting 1 hour), patients will listen to a playlist delivered through specialized headphones, which will either consist of their own selected music (preferred music), music chosen by a music therapist, or no music at all, in a randomized order. Patients will track their pain levels throughout the infusion period and in the intervals between treatments (5 weeks) using standardized pain assessment tools. Additionally, the investigators will assess the subjective experiences of ketamine through interviews and qualitative analysis, while documenting and summarizing any adverse effects. The investigators hypothesize that listening to preferred music will enhance both the intensity and duration of pain relief from IV ketamine. To test this, the investigators will recruit patients already receiving repeated IV ketamine infusions for pain management at the AEPMU clinic. The first infusion will take place under usual conditions to establish a baseline. The infusions will occur in a dedicated room equipped with audio technology to ensure an immersive music experience.
CONDITIONS
Official Title
Music as an Adjunct to Ketamine Therapy for Chronic Pain
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of chronic pain lasting at least 3 months from noncancer causes with moderate to severe intensity (rating 4 or higher on a 0-10 scale)
- Prescribed intravenous ketamine treatment at the Alan Edwards Pain Management Unit
- At least one prior ketamine infusion session at AEPMU that was well tolerated without important adverse effects
- Ability to use an electronic device such as a computer, tablet, or smartphone to complete questionnaires and diaries
- No contraindications for IV ketamine including poorly controlled cardiovascular disease, pregnancy, history of psychosis, moderate to severe liver disease, elevated intracranial or extraocular pressure, or history of substance abuse
- Willingness to avoid grapefruit juice on the day of ketamine infusions due to metabolism interactions
You will not qualify if you...
- Poor tolerability or ineffectiveness of previous intravenous ketamine treatment
- Current diagnosis or treatment for cancer
- Significant hearing impairment not corrected by aids or unwillingness to listen to music during treatment
- Known intellectual disability or autism spectrum disorder
- Risk factors for intracranial hemorrhage such as past significant trauma, known aneurysm, or previous brain surgery
- Clinically relevant diseases including kidney or liver impairment, recent heart attack, cerebrovascular disease, hepatitis B or C, AIDS, or seizure disorders
- Substance use disorder within the past year (except caffeine or nicotine) as defined by DSM-5
- Current acute psychotic symptoms or suicidal thoughts as judged by the referring clinician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Montreal General Hospital
Montreal, Quebec, Canada, H3G 1A4
Actively Recruiting
Research Team
M
Mark A Ware, MD
CONTACT
C
Carlos Gevers-Montoro, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here